F
Fabio A.B. Schutz
Researcher at Harvard University
Publications - 86
Citations - 9410
Fabio A.B. Schutz is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 29, co-authored 81 publications receiving 7604 citations. Previous affiliations of Fabio A.B. Schutz include Niigata University & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC).
Raphael Brandao Moreira,Rana R. McKay,Wanling Xie,Daniel Y.C. Heng,Guillermo Velasco,Daniel Castellano,Andre P. Fay,Fabio A.B. Schutz,Connor Wells,JoAnn Hsu,Sumanta K. Pal,Jae-Lyun Lee,Robert J. Motzer,Darren R. Feldman,Toni K. Choueiri +14 more
TL;DR: A retrospective multicenter study of pts with metastatic nccRCC treated with PD1/PDL1 inhibitors finds that their activity in nCCRCC is poorly characterized, and their response rate by RECIST, time-to-treatment failure (TTF), and overall survival (OS) are summarized.
Journal ArticleDOI
Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls.
TL;DR: These two trials provide several key concepts and definitions that need to be considered when designing new trials and interpreting results in the second-line setting, and a strict definition of what is ‘second line’ is needed.
Journal ArticleDOI
Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials
TL;DR: ICIs provide higher rates of CR compared to SOC, even higher in patients with PD-L1 positive tumors, and this data was confirmed for patients treated with the combination of ICIs plus anti-VEGFR tyrosine kinase inhibitors.
Journal ArticleDOI
Pneumonitis associated with mTOR therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings, and correlation with clinical outcome.
Donnette A. Dabydeen,Jyothi P. Jagannathan,Nikhil H. Ramaiya,Katherine M. Krajewski,Fabio A.B. Schutz,Daniel C. Cho,Ivan Pedrosa,Toni K. Choueiri +7 more
TL;DR: Preliminary data suggest that pneumonitis maybe a marker of therapeutic benefit in patients given mTOR inhibitor treatment and is seen in up to one third of pts.
Journal ArticleDOI
Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)
Fernando C. Maluf,Felipe Moraes Toledo Pereira,Pedro Luiz Serrano Usón,Diogo Assed Bastos,Diogo Augusto Rodrigues da Rosa,Evanius Garcia Wiermann,Fabio A.B. Schutz,Fábio Roberto Kater,Fernando Nunes Galvão de Oliveira,Fernando Sabino Marques Monteiro,Fernando Vidigal de Pádua,Francisco Javier Orlandi,Helena Paes de Almeida Saito,Mouna Ayadi,Pamela Salman Boghikian,Ray Antonio Manneh Kopp,Ricardo Saraiva de Carvalho,Rodrigo Nogueira Fogace,Sandro Roberto De Araujo Cavallero,Sergio Aguiar,Vinicius Carreira Souza,Silke Gillessen Sommer,Silke Gillessen Sommer +22 more
TL;DR: In this article, international guideline recommendations may not always be extrapolated to developing countries where access to resources is limited, and the authors proposed a method to extrapolate guideline recommendations for metastatic castration-sensitive prostate cancer (mCSPC).